A letter from IDRI


Photo of Corey Casper, MD, MPH
Corey Casper, MD, MPH, joined IDRI as its Chief Medical Officer to lend his clinical trials expertise as IDRI moves more products through the pipeline.

In the world of research and development, we often speak of new discoveries that lead to innovation. While this is a hugely important part of science, innovation is not enough.

For new technologies – vaccines, drugs, diagnostics – to reach people who need them, local involvement, production, acceptance and uptake is critical.

In the future, resource-limited countries will produce solutions to their own problems – whether it’s to combat an endemic disease like tuberculosis or to mount a rapid response to an emerging disease outbreak such as Zika or Ebola. IDRI is proud to play a pioneering role in enabling state-of-the-art technologies – not yesterday’s leftovers but innovation to be embraced by those in need – to be produced on the ground in developing countries and delivered at a cost that is viable for all. For the first time, those in need will be among the first to receive the solutions as opposed to the last.

At IDRI, we are focused on adjuvant formulations that have an excellent record of safety and can be manufactured at centers around the world to decrease cost while increasing speed of development. Through local partnerships, production and transfer of this technology, we have the opportunity to make effective vaccines more available in sub-Saharan Africa, Asia and Latin America.

We’ve shown this through our work in creating Afrigen, a South Africa-based company focused on developing and manufacturing vaccines and biologics. In Brazil, we’re collaborating with two biotech organizations, sharing vaccine formulation technology with Cimatec and manufacturing antigen for Orygen’s schistosomiasis vaccine clinical trial. IDRI recently partnered with Quratis, a biotech located in South Korea, to enable the cost-effective production of human and veterinary vaccines that can be widely distributed across Asia and the rest of the world.

Photo of children
Translating our technologies to other countries and moving our products into clinical trials will help relieve the burden of infectious disease.

There’s another side to the translation taking place here at IDRI: moving our research into clinical trials, a critical step in the development of new infectious disease products.

This year, we are concluding a Phase 2a trial in South Africa of IDRI’s tuberculosis vaccine candidate to determine the vaccine’s safety and ability to induce a potent immune response. We also moved our leprosy vaccine candidate into clinical development here in the U.S.; this is a huge step forward for the first vaccine developed solely for protection against this devastating disease.

Soon, we’ll have news to share about three more clinical trials we are taking part in. And, we are moving our most promising preclinical products, including vaccines against Zika virus, pandemic influenza and varicella, from the bench to people across the world who need protection from these emerging threats.

At IDRI, innovation and translation go hand-in-hand as we explore new opportunities that will help us fulfill our mission. As we approach our 25th anniversary in 2018, you’ll see IDRI:
•    Expand our infectious disease focus to include more viral diseases and oncological targets
•    Use our expertise to contribute to elimination campaigns for neglected tropical diseases
•    Explore the potential of using our vaccines and adjuvants as therapies
•    Determine how to increase efficacy of existing vaccines using our adjuvants
•    Refine our RNA vaccine platform, allowing faster vaccine development during disease outbreaks

We are committed to improving the health of all people. By translating our technologies to others and by moving our products forward in clinical development, we can achieve this goal.

The translation of IDRI’s work from bench to bedside brings new infectious disease solutions to those who need them most.



By the Numbers

Year IDRI was founded
Number of employees
Number of PhD/MD scientists
Number of collaborators

Supporters + Collaborators + Teammates